The CDER Medical Policy Council’s review of “breakthrough therapy” designation requests for specific products and indications marks a departure from the council’s charge to take a big picture approach to addressing broader, non-product-specific policy challenges.
Nevertheless, the task of reviewing the growing number of breakthrough requests has been handed to the council to ensure consistency of decisions under the new regulatory pathway created by the...